Wanbury
Wanbury Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Wanbury Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Wanbury Ltd trades at a P/E of 14.13× and P/B of 15.18×.
Valuation
Profitability
Growth
Financial Health
Wanbury Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Wanbury Ltd, switchable between annual and quarterly views, consolidated or standalone.
Wanbury Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹963.8 Cr and reported EPS of ₹19.43.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 374 | 374 | 367 | 393 | 511 | 500 | 576 | 600 |
| Other Income | 76 | 77 | 1 | 2 | 2 | 1 | 3 | 3 |
| Total Income | 450 | 450 | 369 | 395 | 513 | 501 | 579 | 603 |
| Cost of Goods Sold (COGS) | 174 | 174 | 176 | 217 | 300 | 303 | 303 | 294 |
| Gross Profit | 200 | 200 | 192 | 175 | 211 | 197 | 273 | 305 |
| +Operating Expenses | 268 | 267 | 168 | 157 | 176 | 174 | 203 | 229 |
| EBITDA | -67 | -68 | 23 | 18 | 35 | 23 | 70 | 76 |
| +Non-Operating Expenses | 41 | 41 | 125 | 33 | 108 | 33 | 68 | 50 |
| Profit Before Tax (PBT) | -32 | -32 | 65 | -12 | 81 | -10 | 56 | 30 |
| +Tax Expense | -0 | -0 | 0 | 0 | -0 | 0 | 0 | -1 |
| Profit After Tax (PAT) | -32 | -32 | 64 | -13 | 81 | -10 | 56 | 31 |
| Earnings Per Share (EPS) | -13.49 | -13.49 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 |
| Diluted Shares Outstanding (Nos.) | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| +Additional Disclosures | 657 | 657 | 562 | 624 | 809 | 813 | 850 | 868 |
| Sales Growth % | — | -0.15 | -1.65 | 6.82 | 30.23 | -2.26 | 15.21 | 4.15 |
| YoY Sales Growth % | — | -0.15 | -1.65 | 6.82 | 30.23 | -2.26 | 15.21 | 4.15 |
| Material Cost % | 34 | 34 | 40 | 54 | 60 | 52 | 50 | 46 |
| Employee Cost % | 23 | 23 | 18 | 16 | 15 | 16 | 15 | 17 |
| Other Cost % | 48 | 48 | 27 | 24 | 20 | 19 | 20 | 21 |
| OPM % | -18 | -18 | 6 | 5 | 7 | 5 | 12 | 13 |
| Tax % | 1 | 1 | 0 | -2 | -0 | -1 | 1 | -3 |
| Profit Growth % | — | 0.00 | 301.39 | -119.56 | 746.33 | -112.76 | 638.26 | -45.44 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | -78 | -78 | 14 | 8 | 24 | 11 | 57 | 63 |
Wanbury segment analysis: revenue and profit mix.
Disclosed business segments at Wanbury with their share of revenue and profit, switchable between consolidated and standalone reporting.
Wanbury discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Wanbury Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Wanbury Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Wanbury Ltd's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Astounding 1197% quarterly profit growth indicates robust operational efficiency and strong turnaround.
Impressive Return on Equity (ROE) of 76.50% demonstrates excellent profit generation from shareholder investments.
High Return on Capital Employed (ROCE) of 36.70% shows effective capital utilization.
Strong 24.50% quarterly sales growth reflects robust market demand and effective strategies.
Dual manufacturing of formulations and APIs provides vertical integration, enhancing efficiency and control.
What can break it.
High debt-to-equity ratio of 2.98 indicates substantial financial leverage and associated risks.
Negative long-term EPS growth over 3Y (-29.12%) and 5Y (-19.68%) is concerning.
Book value per share declined by 29.33% over 5 years, indicating value erosion.
Zero dividend yield (0.00%) may deter income-focused investors seeking regular returns.
High beta of 2.12 suggests significant stock price volatility, increasing investment risk.
What would change my mind.
Trim if P/E re-rates above 18. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Wanbury Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Wanbury Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Wanbury Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Wanbury Ltd — derived from the live tape, not yesterday's close.
Wanbury Ltd last traded at ₹274.55 with an intraday range of ₹255.9–₹284 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹274.55| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 343.27 | +68.72 | +25.03% |
| R3 | 315.17 | +40.62 | +14.79% |
| R2 | 299.58 | +25.03 | +9.12% |
| R1 | 287.07 | +12.52 | +4.56% |
| PIVOT | 271.48 | -3.07 | -1.12% |
| CURRENT | 274.55 | — | — |
| S1 | 202.77 | -71.78 | -26.15% |
| S2 | 230.87 | -43.68 | -15.91% |
| S3 | 243.38 | -31.17 | -11.35% |
| S4 | 258.97 | -15.58 | -5.68% |
WANBURY is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 258.5 ~ 261
Trading Above opening range, showing Bullishness
Wanbury Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Wanbury Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Wanbury Ltd stood at 53.4% of traded volume, against a 20-day average of 55.3%.
Wanbury announcements: results, concalls, ratings, M&A.
Filings Wanbury sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Wanbury files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 60 documents below.
Press Release
Wanbury Limited has informed the Exchange regarding a press release dated June 02, 2026, titled "Press Release on Q4 & Year ended FY 2026 Audited…
Press Release
Wanbury Limited has informed the Exchange regarding a press release dated April 28, 2026, titled "Press release on MFDS (Ministry of Food and Drug…
General Updates
Wanbury Limited has informed the Exchange about General Updates
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Wanbury Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Wanbury Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Investor decks & rating reports.
Wanbury dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Wanbury has declared, sequenced by announce and record date.
Wanbury corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Wanbury Ltd: business, sector, key facts.
What Wanbury Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Wanbury Ltd operates in the Healthcare, listed as NSE: WANBURY, BSE: 524212.
Wanbury Limited is a pharmaceutical company based in Navi Mumbai, India, established in 1988 (formerly known as Pearl Organics Limited). The company's core business is the manufacturing and sale of both pharmaceutical formulations and active pharmaceutical ingredients (APIs). This dual approach allows for vertical integration within their supply chain, potentially increasing efficiency and control over product quality and cost.
Wanbury's formulations cater to a broad range of therapeutic areas. Their product portfolio includes medications for gynecological conditions, orthopedic issues, hematological disorders (related to blood), diabetes, gastrointestinal problems, stroke recovery, and common ailments like coughs and colds. Additionally, they offer formulations addressing pain (analgesics), inflammation (anti-inflammatories), and other general practitioner needs. The diversification across therapeutic areas likely reflects a strategy to mitigate risk and tap into various market segments.
Complementing their formulations business, Wanbury also produces a significant range of APIs. These are the fundamental chemical compounds used to create finished pharmaceutical products. Wanbury's API production focuses on key therapeutic areas, including diabetes (anti-diabetic APIs), pain relief (anti-analgesic APIs), depression (anti-depressant APIs), allergies (anti-histaminic APIs), inflammation and arthritis (anti-inflammatory and anti-arthritis APIs), blood clotting disorders (anti-thrombotic APIs), epilepsy (anti-epileptic APIs), and high blood pressure (anti-hypertensive APIs). This API production provides a strong foundation for their own formulations and also allows them to potentially supply other pharmaceutical companies.
In summary, Wanbury's business model integrates both the manufacturing of formulations for direct sale and the production of APIs, a crucial component in the pharmaceutical industry's supply chain. Their extensive product portfolio targeting diverse therapeutic areas demonstrates a strategy for market diversification and sustained growth. Their presence both domestically in India and internationally positions them within a global pharmaceutical landscape.
Questions investors ask about Wanbury Ltd (WANBURY).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Wanbury Ltd (WANBURY)?
The current share price of Wanbury Ltd (WANBURY) is ₹274.55. Today, the stock has gained by ₹18.60 (7.27%), trading in a range of ₹255.9 to ₹284. The stock opened at ₹261 with a trading volume of 1,75,811 shares.
02Is Wanbury Ltd stock a good investment for long-term?
Wanbury Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹963.8 crores, P/E ratio of 14.13, ROE of 0.00%, and ROCE of 36.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Wanbury Ltd stock?
The 52-week high price of Wanbury Ltd (WANBURY) is ₹0, while the 52-week low is ₹0. Currently trading at ₹274.55, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Wanbury Ltd stock at the current price?
Whether to buy Wanbury Ltd stock at ₹274.55 depends on multiple factors. The stock is currently trading with a P/E ratio of 14.13 and P/B ratio of 15.18. Today's performance shows a gain of 7.27%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Wanbury Ltd and when is the next dividend?
Wanbury Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹274.55, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Wanbury Ltd?
Wanbury Ltd's key financial metrics include: P/E Ratio: 14.13, P/B Ratio: 15.18, ROE: 0.00%, ROCE: 36.70%, Dividend Yield: 0.00%, EPS: ₹19.43, Book Value: ₹18.09, and Debt-to-Equity: 0.00. The company's market cap stands at ₹963.8 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Wanbury Ltd stock performing today in the market?
Wanbury Ltd stock opened at ₹261 and is currently trading at ₹274.55, showing a gain of ₹18.60 (7.27%). The intraday high is ₹284 and low is ₹255.9. The trading volume stands at 1,75,811 shares, indicating moderate market participation today.
08What is the P/E ratio of Wanbury Ltd and what does it indicate?
Wanbury Ltd has a Price-to-Earnings (P/E) ratio of 14.13, which means investors are willing to pay ₹14.13 for every ₹1 of earnings. With an EPS of ₹19.43, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Wanbury Ltd (WANBURY) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Top quality scorecard stocksScreener
- EMA Crossover ScreenerScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy